Five Democratic members of Congress are calling on President Obama to use the naming of a new drug czar as an opportunity to take a big step toward fully embracing a drug policy based on science, reason, and facts. The five representatives made their call in a letter sent to the White House Thursday.
The White House Office of National Drug Control Policy (the drug czar’s office) is charged with advising the president on drug control issues, setting federal drug control policy, and producing an annual report on national drug control strategy. Its current head, former Seattle police chief Gil Kerlikowske, is resigning to take on the position of commissioner of Customs and Border Protection.
“We commend you and your Administration on the recent steps you have taken to pursue smarter sentencing and policies that respect state laws regarding marijuana,” the congressmen wrote. ”We urge you to nominate a new director of ONDCP who will develop policies based on science rather than ideology and move away from the failed policy of criminalizing marijuana. The new director should promote fact-based education and use medical science and behavioral research to end the questionable practice of equating marijuana with dangerous drugs like heroin, crack, and methamphetamine.”
The signatories are US Representatives Steve Cohen (D-TN), Earl Blumenauer (D-OR), Sam Farr (D-CA), Mark Pocan (D-WI), and Jared Polis (D-CO).
The congressmen noted that the position of drug czar has historically been filled by individuals with law enforcement backgrounds who have viewed drug policy as a matter of criminal enforcement rather than as a matter of public health — regardless of the medical science and public research available. That needs to change, they said.
“We ask that you break from this tradition and nominate someone with a background in science,” the letter said. ”Particularly in light of the rapidly growing public support for marijuana legalization and broader drug policy reform, it would be a mistake for you to appoint someone who merely continues to prosecute the failed war on drugs.”
Instead, they wrote, “the new director of ONDCP should promote scientific research into the benefits and risks of marijuana legalization and be guided by the results of those findings. He or she should take note of the growing movement at the state level to make marijuana legal for medical or personal use and help shape national policies based on the lessons learned in those states. At a minimum the new director should urge strict adherence to the recent DOJ guidelines regarding criminal enforcement in those states.”
It has been nearly six weeks since Kerlikowske’s pending resignation was announced, but there has so far been little hint of who the White House has in mind to replace him. The congressmen are suggesting that it’s time to break the mold and head in a new direction.